A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.
Co-founder and CEO Dr. Tim Lu, (M.D.,Ph.D.) is an Associate Professor at MIT in Biological Engineering, Electrical Engineering and Computer Science and co-founder of Synlogic, Tango TherapeuticsTango Therapeutics, Sample6, Eligo BiomX and Engine Biosciences. In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as Chief Scientific Officer. Senti’s Chief Financial Officer Curt Herberts also comes from Sangamo.